In Vivo Star Anti-Mouse CD274 (PD-L1) / VEGF-A Bispecific Antibody
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD274 (PD-L1) / VEGF-A Bispecific Antibody(克隆 10F.9G2 / B20-4.1.1) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 PD-L1(别名 PDL1 CD274 等)。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD274 (PD-L1) / VEGF-A Bispecific Antibody(克隆 10F.9G2 / B20-4.1.1) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 PD-L1(别名 PDL1 CD274 等)。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
514201 | 1 mg | ¥11,865
514202 | 5 mg | ¥40,341
514203 | 25 mg | ¥121,023
514501 | 1 mg | ¥11,865
514502 | 5 mg | ¥40,341
514503 | 25 mg | ¥121,023
514801 | 1 mg | ¥11,865
514802 | 5 mg | ¥40,341
514803 | 25 mg | ¥121,023
Product Details
Application|Functional assay, Neutralization, animal model study
Product Description|In Vivo Grade Recombinant Anti-mouse PD-L1 / VEGF-A Bispecific Antibody
Regulatory Status|RUO
Endotoxin
Storage Conditions|4ºC
Recommended Usage|This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
See All Formats|Clone 10F.9G2 / B20-4.1.1
Background Information
Programmed Death-Ligand 1 (PD-L1), also known as CD274, is a transmembrane protein expressed on tumor cells, antigen-presenting cells, and various immune cells within the tumor microenvironment. Its primary function is to bind to the inhibitory receptor PD-1 on activated T cells, leading to suppression of T cell activation, cytokine release, and cytotoxic function. This PD-1/PD-L1 interaction is crucial for maintaining peripheral immune tolerance and preventing autoimmunity. However, tumors exploit this pathway by overexpressing PD-L1 to evade immune detection and destruction. Blocking PD-L1 restores T cell activity and has become the foundation of modern cancer immunotherapy, leading to the development of agents such as atezolizumab, durvalumab, and avelumab, which have transformed treatment for several cancers including lung, bladder, and liver cancer.
Vascular Endothelial Growth Factor A (VEGF-A) is a key regulator of angiogenesis, the process of forming new blood vessels. Under normal conditions, VEGF-A supports tissue growth, repair, and oxygen delivery. In cancer, however, VEGF-A is often overexpressed and drives the formation of abnormal and leaky blood vessels, creating a hypoxic and immunosuppressive tumor microenvironment. This dysfunctional vasculature limits immune cell infiltration, supports tumor survival, and contributes to resistance against immunotherapies. Therefore, targeting VEGF-A not only suppresses tumor angiogenesis but can also normalize tumor vasculature to improve immune access to the tumor site.
A bispecific antibody targeting PD-L1 and VEGF-A combines two powerful therapeutic mechanisms into a single molecule—immune checkpoint blockade and angiogenesis inhibition. Blocking PD-L1 reactivates exhausted T cells, allowing the immune system to attack cancer cells effectively. Simultaneously, inhibition of VEGF-A reduces vascular abnormality and improves oxygenation, alleviating hypoxia-induced immunosuppression and facilitating T cell infiltration into the tumor. This dual targeting strategy synergistically enhances anti-tumor immunity while potentially reducing treatment resistance seen with single-agent therapy. Furthermore, one bispecific antibody may optimize pharmacokinetics and safety by minimizing overlapping toxicities compared to combination regimens.
Clinically, PD-L1 × VEGF-A bispecific antibodies are being explored in several solid tumors, including non-small cell lung cancer and hepatocellular carcinoma. Early studies have shown that these agents can elicit stronger immune responses and more durable tumor regression than monotherapies. By bridging immune activation with vascular normalization, PD-L1/VEGF-A bispecifics represent a promising next-generation approach to overcome immune resistance and improve outcomes in oncology.
Data Sheets
Cat # Size Price Quantity 5142011 mg Add to Cart5142025 mg Add to Cart51420325 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). In Vivo Star Anti-Mouse CD274 (PD-L1) / VEGF-A Bispecific Antibody(514201)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd274-pd-l1-vegf-a-bispecific-antibo.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Mouse CD274 (PD-L1) / VEGF-A Bispecific Antibody(514201). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd274-pd-l1-vegf-a-bispecific-antibo.html
@misc{biocsp_item_in_vivo_star_anti_mouse_cd274_pd_l1_vegf_a_bispecific_antibo,
title = {In Vivo Star Anti-Mouse CD274 (PD-L1) / VEGF-A Bispecific Antibody(514201)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd274-pd-l1-vegf-a-bispecific-antibo.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源